William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'
Tweet Send to a Friend
William Blair analyst Matt Phipps reiterated an Outperform rating on Janux Therapeutics (NASDAQ: JANX).The analyst comments "On Monday, December 2 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
